LGND — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
$314.10
Market Cap
$6.26B
52W High
$326.63
52W Low
$166.10
ADV30
213,016
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 51,722,000 | 48,449,000 | 17,368,000 | -13,345,000 | 1,532,105,000 | 115,077,000 | 534,783,000 |
| Dec 2025 | 59,666,000 | 56,674,000 | 20,040,000 | 44,784,000 | 1,560,637,000 | 174,927,000 | 543,425,000 |
| Sep 2025 | 115,461,000 | 111,660,000 | 54,098,000 | 117,273,000 | 1,476,772,000 | 139,376,000 | 526,601,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$123,495,000
Investing CF
$-476,563,000
Financing CF
$418,837,000
CapEx
$-9,507,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$7.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$594,743,000
Inventory
$11,466,000
Receivables
$54,798,000
ST Investments
$676,479,000
EBIT TTM
$190,476,000
Pretax Income TTM
$184,881,000
Interest Exp TTM
$5,595,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$290,542,016
EBITDA
$133,011,000
Free Cash Flow
$139,748,880
Enterprise Value
$5,444,777,472
Total Cash
$1,357,757,952
Total Debt
$1,131,453,056
Shares Out
19,935,609
Trailing EPS
$9.70
Book Value
$48.57
ROE
22.0%
ROA
4.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 268,087,000 | 47,199,000 | 124,453,000 | 1,560,637,000 | 543,425,000 | 1,017,212,000 | 49,359,000 |
| Dec 2024 | 167,133,000 | 23,021,000 | -4,032,000 | 941,774,000 | 111,335,000 | 830,439,000 | 97,047,000 |
| Dec 2023 | 131,314,000 | 9,821,000 | 52,154,000 | 787,216,000 | 86,303,000 | 700,913,000 | 49,577,000 |
| Dec 2022 | 196,245,000 | 3,037,000 | -33,361,000 | 762,668,000 | 165,183,000 | 597,485,000 | 137,850,000 |
TTM Snapshot
Revenues TTM
$189,234,000
NetIncome TTM
$-59,492,000
OpCashFlow TTM
$0
Assets (Latest)
$1,560,637,000
Forward EPS
$11.93
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $220.00 · spot: $314.10 · call volume: 57 · put volume: 38Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LQDA | Liquidia Corp | $6.59B | $73.67 | — |
| BLTE | BELITE BIO, INC | $6.68B | $165.93 | — |
| ALKS | Alkermes plc. | $6.74B | $40.15 | — |
| TVTX | Travere Therapeutics, Inc. | $5.80B | $61.57 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.79B | $98.56 | — |
News headlines (Yahoo Finance, 1h cache)
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
2026-09-22 13:02 · Yahoo
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
2026-09-22 13:00 · Yahoo
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
2026-09-22 11:00 · Yahoo
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
2026-08-26 17:02 · Yahoo
Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock
2026-08-14 20:02 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run
2026-08-14 11:11 · Yahoo
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?
2026-08-13 21:09 · Yahoo
Ligand (LGND) Q2 2026 Earnings Call Transcript
2026-08-13 13:13 · Yahoo
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...
2026-08-06 23:18 · Yahoo
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary
2026-08-06 22:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.